Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19696329 | 0.90 | POLB (0.34) | POLBKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL434137 | 0.87 | POLB (0.35) | POLBKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL438284 | 0.85 | POLB (0.34) | POLBKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL435138 | 0.84 | KEAP1 (0.35) | POLBKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL435841 | 0.84 | POLB (0.34) | POLBKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL435139 | 0.84 | POLB (0.34) | POLBKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL436545 | 0.83 | MAPT (0.41) | POLBKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL460299 | 0.82 | ELANE (0.35) | KMT2AMEN1LMNASMN1; SMN2KDM4E | |
| SCHEMBL1648290 | 0.79 | METAP2 (0.39) | POLBKMT2AMEN1KEAP1NFE2L2 | |
| SCHEMBL436931 | 0.78 | KMT2A (0.35) | POLBKMT2AMEN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839623-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839623-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839623-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-9266896-B2 | Tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2595988-B1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2595988-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-05-16 | — | — | US | disclosed |
| WO-2012012642-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012642-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123235-A1 | Tricyclic Compounds and Methods of Making and Using Same | CES2, DNPEP, METAP2 | POLB 2068/4885KMT2A 916/4885MEN1 1228/4885 |
| US-20160354338-A1 | TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | CES2, DNPEP, METAP2 | POLB 2068/4885KMT2A 916/4885MEN1 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.